ClinicalTrials.gg
CompletedNCT04704245Updated Jan 11, 2021

Effectiveness of Epidermal Growth Factor-containing Ointment on the Solar Lentigines

An interventional study of epidermal growth factor (EGF)-containing ointment and Vehicle ointment in Epidermal Growth Factor, Nd-yttrium Aluminum Garnet Laser and Hyperpigmentation, sponsored by Hallym University Kangnam Sacred Heart Hospital. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-01-11.

Sponsored by Hallym University Kangnam Sacred Heart Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 years 5 months after the study started (first participant enrolled Jul 2017, registered Jan 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Study summary

Subjects were randomly assigned to groups for treatment with either an EGF-containing ointment (the study group) or the vehicle alone (petrolatum; the control group). The EGF ointment included recombinant human EGF (1 μg/g). Random numbers used for assignment to groups were provided by the randomization function of SAS.

The subjects received one session of laser treatment with a Q-switched (QS) 532-nm Nd:yttrium aluminum garnet (YAG) laser of their solar lentigines after enrollment. . The end point of laser treatment for lentigines was immediate whitening. The subjects then applied the EGF ointment or vehicle twice daily (morning and evening) to the lesion for 4 weeks after laser treatment.

02

Conditions studied

  • Epidermal Growth Factor
  • Nd-yttrium Aluminum Garnet Laser
  • Hyperpigmentation
  • Post Inflammatory Hyperpigmentation

Browse trials for

03

In context

Hyperpigmentation

128 studies on the registry are indexed under Hyperpigmentation; 28 are open to participants now.

This study's enrollment of 40 is above the median of 32 across 114 interventional studies indexed under Hyperpigmentation.

Browse Hyperpigmentation studies →

Lead sponsor

Hallym University Kangnam Sacred Heart Hospital is the lead sponsor of 34 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of solar lentigines that occurred after adulthood
  • age of 20 years or older.

Exclusion criteria

Exclusion Criteria:

  • uncontrolled systemic or chronic disease
  • to the ingredients of the ointment
  • current use of skin whitening agents
  • a history of other laser treatments within the past 6 months
  • pregnancy
  • lactation.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    epidermal growth factor (EGF) containing ointment group

    The subjects received one session of laser treatment with a Q-swithced (QS) 532-nm Nd:yttrium aluminum garnet (YAG) laser after enrollment. The procedure parameters were as follows: 5-10-ns pulse duration, 3.5-mm spot size, 0.9-1.1-J/cm2 fluence, and 2-Hz frequency. The end point of laser treatment for lentigines was immediate whitening. The subjects then applied the epidermal growth factor (EGF) ointment twice daily (morning and evening) to the lesion for 4 weeks after laser treatment.

    Drug: epidermal growth factor (EGF)-containing ointment · Procedure: Q-swithced (QS) 532-nm Nd:yttrium aluminum garnet (YAG) laser

  • Placebo comparator
    Vehicle ointment group

    The subjects received one session of laser treatment with a Q-swithced (QS) 532-nm Nd:yttrium aluminum garnet (YAG) laser of their solar lentigines after enrollment. The procedure parameters were as follows: 5-10-ns pulse duration, 3.5-mm spot size, 0.9-1.1-J/cm2 fluence, and 2-Hz frequency. The end point of laser treatment for lentigines was immediate whitening. The subjects then applied the vehicle ointment twice daily (morning and evening) to the lesion for 4 weeks after laser treatment.

    Drug: Vehicle ointment · Procedure: Q-swithced (QS) 532-nm Nd:yttrium aluminum garnet (YAG) laser

Interventions

  • DrugEpidermal Growth FactorStudies of Epidermal Growth FactorEpidermal Growth Factor pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The subjects applied the epidermal growth factor (EGF) ointment twice daily (morning and evening) to the lesion for 4 weeks after laser treatment.

    Also known as: Easyef Saesal ointment, Daewoong Pharmaceutical Co., Ltd., Seoul, Korea

  • DrugVehicle ointment

    To compare the effect of epidermal growth factor (EGF) ointment, the control subjects applied the vehicle ointment twice daily (morning and evening) to the lesion for 4 weeks after laser treatment.

    Also known as: containing petrolatum

  • ProcedureQ-swithced (QS) 532-nm Nd:yttrium aluminum garnet (YAG) laser

    The subjects received one session of laser treatment with a Q-swithced (QS) 532-nm Nd:yttrium aluminum garnet (YAG) laser of their solar lentigines after enrollment. The procedure parameters were as follows: 5-10-ns pulse duration, 3.5-mm spot size, 0.9-1.1-J/cm2 fluence, and 2-Hz frequency. The end point of laser treatment for lentigines was immediate whitening.

    Also known as: Nd:yttrium aluminum garnet laser (Iris, Bluecore Company Co., Ltd., Busan, Korea)

06

What researchers measure

Primary outcomes

  1. Change of pigmentation by physician's assessment

    The pigment clearance was assessed using a 5-grade percentage improvement scale grade 1, \<0% \[worse\]; grade 2, 0%-25% improvement; grade 3, 26%-50% improvement; grade 4, 51%-75% improvement; grade 5, 76%-100% improvement -\> higher score means better outcomes

    Time frame: Change from baseline pigmentation at 4 weeks

  2. Change of pigmentation by physician's assessment

    The pigment clearance was assessed using a 5-grade percentage improvement scale grade 1, \<0% \[worse\]; grade 2, 0%-25% improvement; grade 3, 26%-50% improvement; grade 4, 51%-75% improvement; grade 5, 76%-100% improvement -\> higher score means better outcomes

    Time frame: Change from baseline pigmentation at 8 weeks

Secondary outcomes

  1. Erythema index

    A spectrophotometer was used to assess the lesion in a room at constant temperature (20-24 °C) and humidity (28%-38%). Skin measurements were performed to determine erythema.

    Time frame: baseline

  2. Erythema index

    A spectrophotometer was used to assess the lesion in a room at constant temperature (20-24 °C) and humidity (28%-38%). Skin measurements were performed to determine erythema.

    Time frame: 2 weeks

  3. Erythema index

    A spectrophotometer was used to assess the lesion in a room at constant temperature (20-24 °C) and humidity (28%-38%). Skin measurements were performed to determine erythema.

    Time frame: 4 weeks

  4. Erythema index

    A spectrophotometer was used to assess the lesion in a room at constant temperature (20-24 °C) and humidity (28%-38%). Skin measurements were performed to determine erythema.

    Time frame: 8 weeks

  5. Melanin index

    A spectrophotometer was used to assess the lesion in a room at constant temperature (20-24 °C) and humidity (28%-38%). Skin measurements were performed to determine pigmentation.

    Time frame: baseline

  6. Melanin index

    A spectrophotometer was used to assess the lesion in a room at constant temperature (20-24 °C) and humidity (28%-38%). Skin measurements were performed to determine pigmentation.

    Time frame: 2 weeks

  7. Melanin index

    A spectrophotometer was used to assess the lesion in a room at constant temperature (20-24 °C) and humidity (28%-38%). Skin measurements were performed to determine pigmentation.

    Time frame: 4 weeks

  8. Melanin index

    A spectrophotometer was used to assess the lesion in a room at constant temperature (20-24 °C) and humidity (28%-38%). Skin measurements were performed to determine pigmentation.

    Time frame: 8 weeks

  9. Transepidermal water loss

    A VapoMeter®(Delfin Technologies Ltd., Kuopio, Finland) was used to assess the lesion in a room at constant temperature (20-24 °C) and humidity (28%-38%). Skin measurements were performed to determine transepidermal water loss

    Time frame: baseline

  10. Transepidermal water loss

    A VapoMeter®(Delfin Technologies Ltd., Kuopio, Finland) was used to assess the lesion in a room at constant temperature (20-24 °C) and humidity (28%-38%). Skin measurements were performed to determine transepidermal water loss

    Time frame: 2 weeks

  11. Transepidermal water loss

    A VapoMeter®(Delfin Technologies Ltd., Kuopio, Finland) was used to assess the lesion in a room at constant temperature (20-24 °C) and humidity (28%-38%). Skin measurements were performed to determine transepidermal water loss

    Time frame: 4 weeks

  12. Transepidermal water loss

    A VapoMeter®(Delfin Technologies Ltd., Kuopio, Finland) was used to assess the lesion in a room at constant temperature (20-24 °C) and humidity (28%-38%). Skin measurements were performed to determine transepidermal water loss

    Time frame: 8 weeks

  13. Patient's subjective satisfaction

    The patient's subjective satisfaction was assessed by questionnaire according to the following: 1, worse; 2, no change; 3, mild improvement; 4, moderate improvement; or 5, significant improvement. higher score means better outcome

    Time frame: 4 weeks

  14. Patient's subjective satisfaction

    The patient's subjective satisfaction was assessed by questionnaire according to the following: 1, worse; 2, no change; 3, mild improvement; 4, moderate improvement; or 5, significant improvement. higher score means better outcome

    Time frame: 8 weeks

07

Study locations

1 site
  • Kangnam Sacred Heart Hospital
    Seoul, Korea, Republic of
08

References and documents

Publications

  • Kim HO, Kim HR, Kim JC, Kang SY, Jung MJ, Chang SE, Park CW, Chung BY. A Randomized Controlled Trial on the Effectiveness of Epidermal Growth Factor-Containing Ointment on the Treatment of Solar Lentigines as Adjuvant Therapy. Medicina (Kaunas). 2021 Feb 13;57(2):166. doi: 10.3390/medicina57020166. PubMed 33668564 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2017 to primary completion in Sep 2018, 14 months.

Of 38 non-industry interventional studies with no phase under Hyperpigmentation, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 27. This study's 14 months is above that.

Counting every sponsor, half of 66 studies reached it within 7 months; a quarter within 3 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2021
First posted
Jan 11, 2021
StartActual
Jul 20, 2017
Primary completionActual
Sep 20, 2018
CompletionActual
Dec 26, 2018
Last update
Jan 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04704245
Lead sponsor
Hallym University Kangnam Sacred Heart Hospital
Responsible party
Bo Young Chung (Principal Investigator, Clinical Professor, Hallym University Kangnam Sacred Heart Hospital) — Principal investigator
First posted
Jan 11, 2021
Start date
Jul 20, 2017
Primary completion
Sep 20, 2018
Completion
Dec 26, 2018
Last update
Jan 11, 2021

Study contacts

Bo Young Chung, M.D., PhD
study chair · Department of Dermatology, Kangnam Sacred Heart Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Epidermal Growth Factor

Start the discussion